<DOC>
	<DOCNO>NCT01423539</DOCNO>
	<brief_summary>This randomize , open-label , multicenter study evaluate efficacy safety navitoclax addition bendamustine rituximab patient relapse diffuse large B-cell lymphoma . Patients randomize receive navitoclax addition bendamustine rituximab bendamustine rituximab alone 6 cycle .</brief_summary>
	<brief_title>A Study Navitoclax Addition Bendamustine Rituximab Patients With Relapsed Diffuse Large B-Cell Lymphoma ( NAVIGATE )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically document diagnosis diffuse large Bcell lymphoma Patients must relapse developed progressive disease follow salvage therapy , must relapse progress follow initial therapy opinion investigator medically unfit receive high dose chemotherapy autologous stem cell transplant ( SCT ) salvage therapy high priority Eastern cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Patients undergone STC must 100 day autologous stem cell infusion prior first dose study drug , must recover transplant related toxicity must adequate bone marrow function define protocol independent growth factor support Patients undergone SCT must adequate bone marrow function define protocol independent growth factor support Adequate coagulation , renal hepatic function Refractory DLBCL History malignancy within 2 year prior initiation study treatment except adequately treat carcinoma situ cervix , basal squamous cell skin carcinoma , lowgrade localized prostate cancer treat surgically curative intent one carry good prognosis , situ ductal carcinoma breast treat lumpectomy ( without radiation ) curative intent Active infection require parenteral antibiotic antiviral antifungal agent Inherited acquire bleed diathesis , anticoagulant drug drug inhibit platelet function , underlying condition predispose abnormal bleeding , refractoriness platelet transfusion Clinically significant cardiovascular disease , New York Heart Association Grade II great congestive heart failure , ventricular tachyarrhythmias require medication within 1 year prior initiation study treatment Positive hepatitis B , hepatitis C HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>